EACS2023: 492 Cabotegravir-rilpivirine long acting: data in real life setting in a large French cohort C. Deschanvres , C. Allavena , R. Palich , D. Rey , A. Cheret , O. Zaegel-Faucher , L. Hocqueloux , for the Dat'AIDS Study Group CHU Nantes, Infectious Diseases Department, Nantes, France, INSERM, EA 1413, Nantes, France, Sorbonne University, Pitié-Salpetrière Hospital AP-HP, Infectious Diseases Department, Paris, France, iPLESP, INSERM 1136, Paris, France, Strasbourg University Hospital, HIV Infection Care Center, Strasbourg, France, CHU Guadeloupe, Point-à-Pitre, France, Institut Cochin, INSERM U 1016, CNRS UMR 8104, Paris, France, Aix-Marseille University, APHM Sainte-Marguerite, Service d'Immuno-hématologie clinique, Marseille, France, CHR Orléans, Infectious Diseases Department, Orléans, France General data Abstract category: Antiretroviral therapy – observational studies Abstract body Purpose: Cabotegravir (CAB) + Rilpivirine (RPV) Long Acting (CR-LA) has shown its efficacy and tolerability in Phase 3 study (ATLAS-2M) and has been commercialized since 12/17/2021 in France for virally suppressed people living with HIV-1 (PLWH) on ART, without resistance mutation to RPV and CAB or A1/A6 viral subtype. Few data in real life is yet available. Method: Observational retrospective multi-center study including all adult PLWH with plasma viral load (pVL) <50 copies/mL who switched to CR-LA (every 2 months) between 12/2021 and 12/2022 in the Dat'AIDS French cohort. Participants with at least one pVL after initiation were analyzed. Main objectives were to evaluate efficacy and tolerability of CR-LA, and to describe viral rebounds (VR) defined as two consecutive pVL>50 copies/mL or one pVL>200 copies/mL. Results: Overall, 1134 subjects were included with a median follow-up of 28[IQR 14-40] weeks. Main characteristics are presented in Table. 12.9% had a history of reported viral failure on ART, including 4% on NNRTI and 2.4% on INSTI. Seven subjects had an A1/A6 viral subtype. Oral lead-in was prescribed in 27.6% of subjects. Eighty subjects (7.1%) stopped CR-LA, after a median follow-up of 75 [34-133] days, for adverse events or patient’s decision (n=46), failure (n=7), and other reasons (n=27). VR was detected in 14 subjects (1.1%) and led to treatment interruption in 7 cases (0.5 %). The seven other subjects remained on CR-LA, and 6/7 had a pVL<50 copies/mL at the last visit. Time to treatment interruption and time to VR using Kaplan-Meier survival analysis are shown in figures. Baseline subjects'characteristics % or median [IQR] n = 1134 Age, years 46 [36-55] Male / female / transgender 78.7 / 20.9 / 0.4 MSM 62 Born in France 64 CDC stage C 11.9 Duration of known HIV infection, years 11 [6-19] Number of previous ART lines 4 [2-7] Zenith HIV RNA, log copies/mL 4.8 [4-5.4] Nadir CD4, /mm 312 [188-466] Baseline CD4, /mm 752 [567-949] Duration of pVL<50 copies/ml, years 6.8 [3.4-11] Conclusions: This study shows a high short-term acceptability and efficacy of CR-LA in a large real life cohort of PLWH. Treatment interruption for VR was rare (0.5%) and analysis of emerging resistance at VR is ongoing. A prolonged follow-up is needed to confirm long term efficacy and tolerability. General conditions 1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after the submission deadline and I am aware that it will be published exactly as submitted.: Yes 2. I confirm that the submission of the abstract constitutes my consent to publication (e.g. conference website, programmes, other promotions, etc.). : Yes 3. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.: Yes 4. I agree that all data provided may be used (saved, stored, processed, transmitted and deleted) in compliance with the privacy policy to provide the services described.: Yes 1,2 1,2 3,4 5 6,7 8 9 1 2 3 4 5 6 7 8 9 3 3 126 19TH EUROPEAN AIDS CONFERENCE | WARSAW 2023
RkJQdWJsaXNoZXIy Mzc2ODc=